Trial Profile

A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lucitanib (Primary)
Indications Advanced breast cancer; Male breast cancer
Focus Therapeutic Use
Sponsors Clovis Oncology [CEASED]

Most Recent Events

18 Jul 2022 Results of a Pop PK pooled analysis from five phase 1 and 2 clinical studies: NCT01283945, NCT02053636, ISRCTN23201971, NCT02202746 and NCT02109016 published in the European Journal of Drug Metabolism and Pharmacokinetics
05 Aug 2019 Status changed to discontinued.
04 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com